Xalatan Approved In Japan For Glaucoma And Ocular Hypertension
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Xalatan Approved In Japan For Glaucoma And Ocular Hypertension

BRIDGEWATER, NJ -- March 15, 1999 -- Pharmacia & Upjohn’s once-a-day glaucoma medication, Xalatan(TM) Sterile Ophthalmic Solution has been approved by Japan's Ministry of Health & Welfare for the treatment of glaucoma and ocular hypertension.

Xalatan has been approved in more than 57 countries and is the leading prescribed glaucoma medication in several markets, including the United States.

Xalatan is related to a class of compounds called prostaglandins that are present in various forms throughout the body. Prostaglandins act locally to increase drainage of aqueous humor, the fluid behind the eye's intraocular lens and reduce intraocular pressure. Lowering intraocular pressure through topical treatments is the standard of care in treating glaucoma.

Related Links: Xalatan, Pharmacia & Upjohn

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities